Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Prognostic significance of left ventricular hypertrophy observed at dialysis initiation depends on the pre-dialysis use of erythropoiesis-stimulating agents.

Hayashi T, Kimura T, Yasuda K, Obi Y, Sasaki K, Iio K, Miyasato K, Kamimura T, Kitamura H, Tsubakihara Y, Rakugi H, Isaka Y.

Clin Exp Nephrol. 2013 Apr;17(2):294-303. doi: 10.1007/s10157-012-0705-4. Epub 2012 Oct 26.

PMID:
23100176
2.
3.

Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.

Bae MN, Kim SH, Kim YO, Jin DC, Song HC, Choi EJ, Kim YL, Kim YS, Kang SW, Kim NH, Yang CW, Kim YK.

PLoS One. 2015 Nov 20;10(11):e0143348. doi: 10.1371/journal.pone.0143348. eCollection 2015.

4.

Electrocardiographic left ventricular hypertrophy and outcome in hemodialysis patients.

Kim SJ, Oh HJ, Yoo DE, Shin DH, Lee MJ, Kim HR, Park JT, Han SH, Yoo TH, Choi KH, Kang SW.

PLoS One. 2012;7(4):e35534. doi: 10.1371/journal.pone.0035534. Epub 2012 Apr 17.

5.

Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.

Ogawa T, Shimizu H, Kyono A, Sato M, Yamashita T, Otsuka K, Nitta K.

Int Urol Nephrol. 2014 Jan;46(1):151-9. doi: 10.1007/s11255-013-0494-z. Epub 2013 Jun 27.

PMID:
23807369
6.

Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression.

Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS.

Kidney Int. 2004 Apr;65(4):1492-8.

7.

Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.

Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, Velazquez EJ, McMurray JJ, Kober L, Pfeffer MA, Califf RM, Solomon SD.

JACC Cardiovasc Imaging. 2008 Sep;1(5):582-91. doi: 10.1016/j.jcmg.2008.05.012.

8.

Echocardiographic changes following hemodialysis initiation in patients with advanced chronic kidney disease and symptomatic heart failure with reduced ejection fraction.

Ganda A, Weiner SD, Chudasama NL, Valeri AM, Jadoon A, Shimbo D, Radhakrishnan J.

Clin Nephrol. 2012 May;77(5):366-75.

PMID:
22551882
10.

Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.

Nishio A, Chhatkuli BP, Ma JZ, Kalantari K.

Blood Purif. 2013;36(1):29-36. doi: 10.1159/000350583. Epub 2013 May 25.

PMID:
23735569
11.

Erythropoiesis-stimulating agents and thrombotic events in dialysis patients.

Suttorp MM, Hoekstra T, Ocak G, van Diepen AT, Ott I, Mittelman M, Rabelink TJ, Krediet RT, Dekker FW.

Thromb Res. 2014 Nov;134(5):1081-6. doi: 10.1016/j.thromres.2014.07.030. Epub 2014 Aug 1.

PMID:
25242244
12.

Relationship between different blood pressure measurements and left ventricular mass by cardiac magnetic resonance imaging in end-stage renal disease.

Merchant A, Wald R, Goldstein MB, Yuen D, Kirpalani A, Dacouris N, Ray JG, Kiaii M, Leipsic J, Kotha V, Deva D, Yan AT.

J Am Soc Hypertens. 2015 Apr;9(4):275-84. doi: 10.1016/j.jash.2015.01.011. Epub 2015 Jan 30.

PMID:
25753299
13.

Pretransplantation erythropoiesis-stimulating agent hyporesponsiveness is associated with increased kidney allograft failure and mortality.

Costa NA, Kshirsagar AV, Wang L, Detwiler RK, Brookhart MA.

Transplantation. 2013 Nov 15;96(9):807-13. doi: 10.1097/TP.0b013e3182a0f668.

14.

Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease.

Foley RN, Curtis BM, Randell EW, Parfrey PS.

Clin J Am Soc Nephrol. 2010 May;5(5):805-13. doi: 10.2215/CJN.07761109. Epub 2010 Apr 8.

15.

Association of echocardiographic abnormalities with mortality in men with non-dialysis-dependent chronic kidney disease.

Payne J, Sharma S, De Leon D, Lu JL, Alemu F, Balogun RA, Malakauskas SM, Kalantar-Zadeh K, Kovesdy CP.

Nephrol Dial Transplant. 2012 Feb;27(2):694-700. doi: 10.1093/ndt/gfr282. Epub 2011 May 25.

16.

The prognostic value of electrocardiographic estimation of left ventricular hypertrophy in dialysis patients.

Covic AC, Buimistriuc LD, Green D, Stefan A, Badarau S, Kalra PA.

Ann Noninvasive Electrocardiol. 2013 Mar;18(2):188-98. doi: 10.1111/anec.12007. Epub 2012 Nov 22.

PMID:
23530490
17.

The prevalence of left ventricular hypertrophy in Chinese hemodialysis patients is higher than that in peritoneal dialysis patients.

Tian JP, Wang T, Wang H, Cheng LT, Tian XK, Lindholm B, Axelsson J, Du FH.

Ren Fail. 2008;30(4):391-400. doi: 10.1080/08860220801964178.

PMID:
18569912
18.

Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging.

Patel RK, Oliver S, Mark PB, Powell JR, McQuarrie EP, Traynor JP, Dargie HJ, Jardine AG.

Clin J Am Soc Nephrol. 2009 Sep;4(9):1477-1483. doi: 10.2215/CJN.03350509.

19.

Left ventricular hypertrophy and endothelial dysfunction in chronic kidney disease.

Poulikakos D, Ross L, Recio-Mayoral A, Cole D, Andoh J, Chitalia N, Sharma R, Carlos Kaski J, Banerjee D.

Eur Heart J Cardiovasc Imaging. 2014 Jan;15(1):56-61. doi: 10.1093/ehjci/jet120. Epub 2013 Jun 27.

PMID:
23811493
20.

Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients.

Minutolo R, Conte G, Cianciaruso B, Bellizzi V, Camocardi A, De Paola L, De Nicola L.

Nephrol Dial Transplant. 2012 Jul;27(7):2880-6. doi: 10.1093/ndt/gfs007. Epub 2012 Feb 8.

PMID:
22319218

Supplemental Content

Support Center